Ginkgo Bioworks Holdings Statistics

Total Valuation

DNA has a market cap or net worth of $456.93 million. The enterprise value is $474.19 million.

Market Cap	456.93M
Enterprise Value	474.19M

Important Dates

The next estimated earnings date is Thursday, May 7, 2026, after market close.

Earnings Date	May 7, 2026
Ex-Dividend Date	n/a

Share Statistics

DNA has 58.21 million shares outstanding. The number of shares has increased by 6.87% in one year.

Current Share Class	46.79M
Shares Outstanding	58.21M
Shares Change (YoY)	+6.87%
Shares Change (QoQ)	+2.60%
Owned by Insiders (%)	17.45%
Owned by Institutions (%)	56.50%
Float	41.14M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.69
Forward PS	2.83
PB Ratio	0.90
P/TBV Ratio	1.01
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	2.79
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.92, with a Debt / Equity ratio of 0.86.

Current Ratio	4.92
Quick Ratio	4.66
Debt / Equity	0.86
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -51.08% and return on invested capital (ROIC) is -18.06%.

Return on Equity (ROE)	-51.08%
Return on Assets (ROA)	-15.42%
Return on Invested Capital (ROIC)	-18.06%
Return on Capital Employed (ROCE)	-30.10%
Weighted Average Cost of Capital (WACC)	6.56%
Revenue Per Employee	$350,835
Profits Per Employee	-$644,872
Employee Count	485
Asset Turnover	0.14
Inventory Turnover	n/a

Taxes

Income Tax	-837,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +0.13% in the last 52 weeks. The beta is 1.57, so DNA's price volatility has been higher than the market average.

Beta (5Y)	1.57
52-Week Price Change	+0.13%
50-Day Moving Average	7.35
200-Day Moving Average	10.06
Relative Strength Index (RSI)	55.28
Average Volume (20 Days)	1,022,395

Short Selling Information

The latest short interest is 6.10 million, so 10.48% of the outstanding shares have been sold short.

Short Interest	6.10M
Short Previous Month	8.00M
Short % of Shares Out	10.48%
Short % of Float	14.82%
Short Ratio (days to cover)	5.42

Income Statement

In the last 12 months, DNA had revenue of $170.16 million and -$312.76 million in losses. Loss per share was -$5.64.

Revenue	170.16M
Gross Profit	123.18M
Operating Income	-308.11M
Pretax Income	-313.60M
Net Income	-312.76M
EBITDA	-267.82M
EBIT	-308.11M
Loss Per Share	-$5.64

Full Income Statement

Balance Sheet

The company has $422.62 million in cash and $439.89 million in debt, giving a net cash position of -$17.27 million or -$0.30 per share.

Cash & Cash Equivalents	422.62M
Total Debt	439.89M
Net Cash	-17.27M
Net Cash Per Share	-$0.30
Equity (Book Value)	508.59M
Book Value Per Share	8.74
Working Capital	375.87M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$171.06 million and capital expenditures -$7.67 million, giving a free cash flow of -$178.72 million.

Operating Cash Flow	-171.06M
Capital Expenditures	-7.67M
Depreciation & Amortization	40.29M
Net Borrowing	-354,000
Free Cash Flow	-178.72M
FCF Per Share	-$3.07

Full Cash Flow Statement

Margins

Gross margin is 72.39%, with operating and profit margins of -181.08% and -183.81%.

Gross Margin	72.39%
Operating Margin	-181.08%
Pretax Margin	-184.30%
Profit Margin	-183.81%
EBITDA Margin	-157.40%
EBIT Margin	-181.08%
FCF Margin	n/a

Dividends & Yields

DNA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.87%
Shareholder Yield	-6.87%
Earnings Yield	-68.45%
FCF Yield	-39.11%

Analyst Forecast

The average price target for DNA is $8.50, which is 8.28% higher than the current price. The consensus rating is "Hold".

Price Target	$8.50
Price Target Difference	8.28%
Analyst Consensus	Hold
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on August 20, 2024. It was a reverse split with a ratio of 1:40.

Last Split Date	Aug 20, 2024
Split Type	Reverse
Split Ratio	1:40

Scores

DNA has an Altman Z-Score of -7.48 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.48
Piotroski F-Score	1